TORONTO – Neurologists at the Alzheimer's Association International Conference (AAIC) this week were keen to understand how the latest anti-amyloid therapies would benefit their patients depending on ...

NEW YORK – Kazia Therapeutics on Friday said it entered into a securities purchase agreement in connection with a private placement of equity securities (PIPE) financing with certain institutional ...

Sanofi will acquire rights to develop and commercialize the drug for $130 million upfront, with Visirna eligible for up to $265 million in milestone payments.

NEW YORK – Silexion Therapeutics on Thursday announced the immediate exercise of certain outstanding warrants to purchase its ordinary shares, allowing it to raise gross proceeds of $1.8 million. The ...

In a Phase II trial, advanced ovarian patients with HRD alterations seemed to fare particularly well on Imunon's IMNN-001 plus standard chemo.

BE-101 is an engineered B-cell therapy, in which a functional copy of the FIX gene is inserted into patients' own B cells in vivo.

NEW YORK – Strong uptake of AstraZeneca's Tagrisso (osimertinib) in the second quarter of 2025 and positive overall survival results from the Phase III FLAURA2 trial have bolstered the firm's ...

NEW YORK – Precision biotech company Anocca will use MaxCyte's cell-engineering technology to produce its pipeline of T-cell receptor T-cell (TCR-T) therapies, including its lead program in ...

The partners will seek CAP/CLIA certification for an organoid-based assay and conduct clinical validation studies of it as a tool to guide treatment.

NEW YORK – Merck is feeling the pressure of future Keytruda (pembrolizumab) patent losses years in advance. In reporting its second quarter 2025 financial results on Tuesday, the Rahway, New ...

The firm is leveraging its expertise in the immuno-oncology space to expedite development of newer agents like the bispecific antibody BNT327.

NEW YORK – ARTBio this week said it has raised $132 million in Series B financing to advance its alpha radioligand therapies and bolster the supply chain underlying their development. The funding ...